Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 165.4% in October

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 130,300 shares, a growth of 165.4% from the September 30th total of 49,100 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average daily volume of 124,600 shares, the days-to-cover ratio is presently 1.0 days. Based on an average daily volume of 124,600 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Greenleaf Trust bought a new position in Alterity Therapeutics in the 2nd quarter valued at about $70,000. HB Wealth Management LLC raised its stake in shares of Alterity Therapeutics by 17.6% in the first quarter. HB Wealth Management LLC now owns 37,483 shares of the company’s stock worth $129,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Twin Lakes Capital Management LLC lifted its holdings in shares of Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after purchasing an additional 133,333 shares in the last quarter. 2.14% of the stock is owned by institutional investors.

Alterity Therapeutics Stock Performance

Shares of ATHE opened at $4.60 on Friday. The stock has a 50-day moving average of $4.63 and a 200-day moving average of $4.49. Alterity Therapeutics has a one year low of $1.00 and a one year high of $7.00.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.00.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.